3rd Quarter 2022 Report (July - September)
Percent change evaluated relative to 3rd Quarter 2021

Summary

- The percentage of prescribers enrolled and querying the PDMP system has stayed consistent for several years (Figure 1 and Table 3).
- Gateway automated queries remained consistent while web queries have increased by 11.5% from the 3rd quarter of 2021 (Table 1).
- Overall, the total number of prescriptions for controlled substances slightly increased (0.2%) since the 3rd quarter of 2021. Gabapentin is the most prescribed substance in the system with a 4.2% increase. While most of the other top prescriptions decreased, stimulant prescriptions showed an increase with amphetamine prescriptions up 18.4% and methylphenidate prescriptions increasing 12.7% (Table 5).

Figure 1. Oregon PDMP Registration: 2013-2022

(Note: Report updated December 2024 to reflect more accurate query count.)

Table 1. PDMP Queries Summary Statistics: July - September 2022.

User Type	Web Portal		Gateway Integration			
	Queries	% Change[1]	Automated Queries	% Change[1]	Reports Viewed	% Change[1]
Healthcare providers	85,814	9.7%	5,797,534	-2.0%	867,427	-9.1%
Pharmacies	87,969	35.0%	1,157,156	11.2%	585,045	13.1%
Delegates	150,204	2.1%	-	-	-	-
Total of all users[2]	**324,051**	**11.5%**	**6,954,690**	**0.02%**	**1,452,472**	**-1.3%**

[1] Percent change evaluated relative to same time period during the prior year.

[2] Query data drawn from Appriss AWARxE web portal, PMPi Gateway audit file and EDIE supplementary audit file. Queries de-duplicated using last name, date of birth, prescriber ID, and date of query

- Web portal queries have increased from the same quarter last year across all user groups, with the largest increase seen in queries by pharmacies.
- The number of integrated automated queries remained consistent and reports slightly decreased over the same quarter last year. Reports viewed decreased for healthcare providers but increased by 13.1% for pharmacies.

Table 2. Special Requests: July - September 2022.

Measure	Count
Patient Records	8
Healthcare Boards	46
Law Enforcement	6
Total Special Requests	**60**

- 60 special requests were received and processed by PDMP staff.
- Healthcare boards were the most frequent originators of these requests.

(Note: Report updated December 2024 to reflect more accurate query count.)

Table 3. PDMP Enrollment and System Use for Prescribers[1]: July – September 2022.

User Type	Prescribers	Enrolled	Web Query	Automated Query	Total Query
All Prescribers (by DEA)	18,962	16,020 / 84.5%	4,983 / 31.1%	12,237 / 76.4%	13,414 / 83.7%
Top 4,000 Prescribers	4,000	3,902 / 97.6%	2,027 / 51.9%	3,512 / 90.0%	3,757 / 96.3%
Top 2,000 Prescribers	2,000	1,967 / 98.4%	1,118 / 56.8%	1,800 / 91.5%	1,914 / 97.3%

[1] Prescriber counts provided by unique DEA Number, but providers may be associated with multiple DEA numbers.

- Table 3 represents only prescribers who wrote a prescription for controlled substances in Oregon in the 3rd quarter (18,962 prescribers).
- The percentage of enrolled prescribers who queried the system has slightly increased since the 3rd quarter of 2021, when 81.2% of enrolled prescribers submitted queries.

Table 4. PDMP Query by Clinical User Group for Enrolled Providers: July – September 2022.

Discipline	Total User Accounts (by DEA)[1]	% Change[2]	Web Users[3,4]	% Change[2]	Integrated Users	% Change[2]
MD/PA/DO	18,575	-1.3%	1,631	-7.7%	14,734	12.1%
NP/CNS-PP	4,536	-6.9%	993	1.1%	3,437	11.5%
RPh	3,059	-21.1%	1,344	-11.8%	429	7.3%
Delegates	2,787	-17.7%	1,620	-9.2%	-	-
DDS/DMD	2,630	-21.6%	400	5.3%	262	5.6%
ND	577	-50.9%	156	11.4%	464	5.2%

[1] Prescriber counts provided by unique DEA Number, but providers may be associated with multiple DEA numbers.

[2] Percent change evaluated relative to same time period during the prior year.

[3] Users that have submitted a query this quarter.

[4] Query data drawn from Appriss AWARxE web portal, PMPi Gateway audit file and EDIE supplementary audit file. Queries de-duplicated using last name, date of birth, prescriber ID, and date of query.

- Table 4 represents usage for only providers who are registered in the PDMP.
- In general, most disciples are increasing usage of the integrated system and decreasing usage of the PDMP through the web portal.
- Patterns of registration are likely driven by state mandated PDMP registration for prescribers and HIT integration efforts undertaken by health care systems.

(Note: Report updated December 2024 to reflect more accurate query count.)

Table 5. Top Prescriptions: July – September 2022.

Drug	Number of Rx	% of all Rx	% Change[1]
All	**1,659,189**	**100%**	**0.2%**
Gabapentin	237,200	14.2%	4.2%
Oxycodone	223,398	13.5%	0.4%
Hydrocodone	223178	13.5%	-5.2%
Amphetamine	205,747	12.4%	18.4%
Methylphenidate	82,380	5.0%	12.7%
Lorazepam	81,680	4.9%	-2.0%
Tramadol	78,395	4.7%	-3.2%
Zolpidem	62,318	3.8%	-5.0%
Alprazolam	58,268	3.5%	-3.6%
Clonazepam	57,139	3.5%	-4.7%

[1] Percent change evaluated relative to same time period during the prior year.

- Gabapentin prescriptions increased relative to 3rd quarter 2021, while hydrocodone decreased and oxycodone slightly increased. Gabapentin was the top prescription (14% of all prescriptions) was added as a PDMP-covered substance January 1st, 2020.
- Prescriptions for common benzodiazepines decreased (i.e., lorazepam, alprazolam, clonazepam), while prescriptions for the stimulants (i.e., amphetamine and methylphenidate) increased.

Table 6. Prescriptions for Buprenorphine and Naloxone: July – September 2022.

Drug	Number of Rx	% of all Rx	% Change[1]
Buprenorphine/Naloxone	43,789	2.6%	1.9%
Buprenorphine	24,155	1.5%	6.5%
Naloxone	9,026	0.5%	60.3%

[1] Percent change evaluated relative to same time period during the prior year.

- Prescriptions for buprenorphine and naloxone and combinations have increased relative to the same quarter last year.

Contact: PDMP Research Analyst, pdmp.research@state.or.us

(Note: Report updated December 2024 to reflect more accurate query count.)